Intended for Healthcare Professionals

VISCO-3 Sodium
Hyaluronate 

OverviewTechnologySpecificationsEducationAdditional InformationPatient ResourcesRelated Products

Overview

VISCO-3™ Sodium Hyaluronate is a purified, high molecular weight hyaluronate used to treat osteoarthritis of the knee that aims to relieve pain1-6, reduce safety risks1-3,7,8 and repeat lasting results◊1-4,6,9,10 with a series of three weekly injections.

Procedures

  • Knee Injection

Philosophies

  • Early Intervention

Application

  • Knee

Relieve

  • Demonstrated superior pain relief to saline and proven non-inferior to Euflexxa® with reported 52% reduction in knee pain at 12 weeks.1§-3
  • Improved pain, balance and physical function as early as one week and up to 6 months.4§
  • Proven superior to saline for Lequesne pain compared to Hymovis®, which failed to demonstrate superiority to saline for WOMAC pain in clinical trial.1§,5
  • VISCO-3 formulation demonstrated a 52% improvement in knee pain and 43% improvement in knee stiffness in a double blind, randomized, multicenter, parallel group study of 223 patients.6§

Reduce

  • No reports of pseudoseptic events or treatment-related allergic reactions across multiple clinical studies.1§-3
  • Integrated analysis recorded fewer participants discontinued knee injection treatment due to adverse events when treated with VISCO-3 formulation than with saline.1§
  • In animal models, VISCO-3 formulation showed less inflammatory response than Hyalgan® and Synvisc®.7#
  • VISCO-3 formulation exhibits higher level of purity than Hyalgan and Synvisc with nearly no detectable impurities.8†

Repeat◊

  • Literature demonstrates no increased safety risk with repeated treatment cycles.2,3
  • A clinical review demonstrated repeat courses of intra-articular HA maintained or improved pain reduction while introducing no increased safety risk.9
  • Proven clinical heritage with over 20 years of repeating lasting results under brand names including Artz®, Artzal®, Supartz® and Supartz FX®.1§,3,4§,6§
  • A retrospective claims analysis of patients receiving a total knee replacement concluded that patients treated with HA knee injection experienced a delay in median time to total knee replacement by up to 2.4 years with three treatment courses; with greater use of HA associated with a longer time to TKR.10

Technology

VISCO-3 is a sterile, viscoelastic non-pyrogenic solution of purified, high molecular weight (620,000-1,170,000 daltons) sodium hyaluronate (hyaluronan) having a pH of 6.8-7.8. Each one mL of VISCO-3 solution contains 10 mg of sodium hyaluronate (hyaluronan) dissolved in a physiological saline (1.0% solution). 

Specifications

Education

Literature

VISCO-3 Sodium Hyaluronate Brochure

VISCO-3 Patient Brochure

Appario Program Brochure

VISCO-3: The Clinical Difference Flyer

VISCO-3 Sodium Hyaluronate Clinical Paper

Summary of double-blind, multi-center, randomized, controlled trial comparing efficacy and safety of VISCO-3 and competitor product.

VISCO-3 Injection Technique

VISCO-3 Sodium Hyaluronate knee injections are to be administrated once a week for 3 weeks (a total of 3 injections).

Indications For Use

VISCO-3 Sodium Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

Before using VISCO-3 Sodium Hyaluronate, ask your patients if they are allergic to hyaluronan products, or products from birds such as feathers, eggs, and poultry. Do not administer to patients with known hypersensitivity to sodium hyaluronate preparations. Use caution when injecting VISCO-3 Sodium Hyaluronate into patients who are allergic to avian proteins, feathers and egg products. VISCO-3 Sodium Hyaluronate is only for injection into the knee, performed by a doctor or other qualified health care professional. VISCO-3 Sodium Hyaluronate injection should not be used in the presence of a skin disease or infection around the area where the injection will be given. VISCO-3 Sodium Hyaluronate has not been tested to show pain relief in joints other than the knee and for conditions other than OA. VISCO-3 Sodium Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. Strenuous or pro-longed weight-bearing activities after treatment are not recommended. The effectiveness of repeat treatment cycles of VISCO-3 Sodium Hyaluronate has not been established. The side effects most commonly seen after injection of VISCO-3 Sodium Hyaluronate in the clinical trial were knee pain, swelling, and/or fluid build-up around the knee. These reactions are generally mild and do not last long. Other conditions, including but not limited to skin redness and rash, knee stiffness were also reported. For complete instructions for use, see the package insert and visit www.zimmerbiomet.com.

This material is intended for US Health Care Professionals.

VISCO-3™ is a trademark of Seikagaku Corporation.

Additional Information

Patient Resources

Patient Access Solutions

Related Products

Gel-One®  Cross-linked hyaluronate

Low-volume single-injection viscosupplement.

Synovasure®  Differential Diagnosis Arthritis Panel

Comprehensive panel of synovial fluid laboratory tests to aid in differentiating common arthritis conditions, incl. OA.

ASC Solutions

Whether you’re looking to open a new facility, add a service line or enhance efficiencies, we have options to help address the most common clinical and economical challenges you face in an Ambulatory Surgery Center.

GPS® III Platelet Concentration System

Tailored resources for your patients.

Find videos, articles, and interactive content to guide your patients throughout their surgical journey on ReadyPatient.com, our dedicated patient recovery site.
Visit The ReadyPatient

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.   

This material is intended for health care professionals. Distribution to any other recipient is prohibited. 

For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert or contact your local representative; search this website for additional product information. To obtain a copy of the current Instructions for Use (IFU) for full prescribing and risk information, please visit labeling.zimmerbiomet.com or call 1-800-348-2759, press 4 for 411 Technical Support.